Stay updated on DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial
Sign up to get notified when there's something new on the DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial page.

Latest updates to the DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoChange DetectedThe webpage has undergone significant updates regarding a Phase 1b clinical study involving DS-8201a and pembrolizumab for advanced breast cancer and NSCLC, with new identifiers and collaborators added, while extensive details about the study's design and inclusion criteria have been removed.SummaryDifference32%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 24, 2025. However, the removal of the date March 25, 2025, indicates a potential change in scheduling or availability.SummaryDifference0.3%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version release, moving from Revision v2.14.2 to v2.14.3, with the last update date changed from February 24, 2025, to March 25, 2025.SummaryDifference0.2%
- Check66 days agoChange DetectedThe reference to 'AstraZeneca UK Limited' has been removed, while 'AstraZeneca' remains mentioned on the page.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has been updated to reflect that the study is now active and not recruiting, with a total of 30 locations listed. Additionally, several past dates and contact information have been removed.SummaryDifference6%
Stay in the know with updates to DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial page.